CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculty of Pharmacy, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France
Nicolas Primas
CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculty of Pharmacy, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France
Sébastien Hutter
IHU Méditerranée Infection, UMR VITROME—Tropical Eukaryotic Pathogens, Aix Marseille University, 19–21 Boulevard Jean Moulin, 13005 Marseille, France
Sandra Bourgeade-Delmas
UMR 152 PHARMA-DEV, University of Toulouse, IRD, UPS, 31062 Toulouse, France
Clotilde Boudot
Faculty of Pharmacy, Institute of Neuroepidemiology and Tropical Neurology, University of Limoges, INSERM U1094, 87025 Limoges, France
Caroline Castera-Ducros
CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculty of Pharmacy, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France
Inès Jacquet
CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculty of Pharmacy, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France
Bertrand Courtioux
Faculty of Pharmacy, Institute of Neuroepidemiology and Tropical Neurology, University of Limoges, INSERM U1094, 87025 Limoges, France
Nadine Azas
IHU Méditerranée Infection, UMR VITROME—Tropical Eukaryotic Pathogens, Aix Marseille University, 19–21 Boulevard Jean Moulin, 13005 Marseille, France
Pascal Rathelot
CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculty of Pharmacy, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France
Patrice Vanelle
CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculty of Pharmacy, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France
As part of our ongoing scaffold-hopping work on an antikinetoplastid 3-nitroimidazo[1,2-a]pyridine scaffold, we explored 3-nitroimidazo[1,2-b]pyridazine as a potential new antikinetoplastid series. Using conditions previously described by our lab, we obtained 6-chloro-3-nitro-2-[(phenylsulfonyl)methyl]imidazo[1,2-b]pyridazine with 54% yield. In vitro activity of this compound was evaluated against both the promastigote form of Leishmania donovani, the axenic amastigote form of Leishmania infantum and the trypomastigote blood stream form of Trypanosomabrucei brucei, and its influence on cell viability was assessed on the HepG2 cell line. However, despite good activity against the trypomastigote blood stream form of T. b. brucei (EC50 = 0.38 µM), it showed poor solubility in both HepG2 (CC50 > 7.8 µM) and L. infantum axenic amastigotes (EC50 > 1.6 µM) culture media, associated with a loss of activity against the promastigote form of L. infantum (EC50 > 15.6 µM).